These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22941027)

  • 21. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orthopaedics: Structural support.
    Berglund J
    Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
    [No Abstract]   [Full Text] [Related]  

  • 23. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
    J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Gollbach KL; Hayman SR; Kumar S; Lust JA; Rajkumar SV; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Bergsagel PL; Fonseca R; Reeder CB; Stewart AK; Roy V; Dalton RJ; Carr AB; Kademani D; Keller EE; Viozzi CF; Kyle RA
    Mayo Clin Proc; 2006 Aug; 81(8):1047-53. PubMed ID: 16901028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
    Suvannasankha A; Chirgwin JM
    Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone complications in multiple myeloma.
    Berenson JR; Rajdev L; Broder M
    Cancer Biol Ther; 2006 Sep; 5(9):1082-5. PubMed ID: 16969119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
    Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
    BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease.
    Mehrotra B
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):561-6. PubMed ID: 26515737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment for myeloma bone disease.
    Yeh HS; Berenson JR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.